These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 11978151)

  • 1. Clinical implications of endotoxin concentrations in vaccines.
    Geier DA; Geier MR
    Ann Pharmacother; 2002 May; 36(5):776-80. PubMed ID: 11978151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serious neurological conditions following pertussis immunization: an analysis of endotoxin levels, the vaccine adverse events reporting system (VAERS) database and literature review.
    Geier DA; Geier MR
    Pediatr Rehabil; 2002; 5(3):177-82. PubMed ID: 12587565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group.
    Schmitt-Grohé S; Stehr K; Cherry JD; Heininger U; Uberall MA; Laussucq S; Eckhardt T
    Dev Biol Stand; 1997; 89():113-8. PubMed ID: 9272341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine.
    Stehr K; Cherry JD; Heininger U; Schmitt-Grohé S; uberall M; Laussucq S; Eckhardt T; Meyer M; Engelhardt R; Christenson P
    Pediatrics; 1998 Jan; 101(1 Pt 1):1-11. PubMed ID: 9417143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group.
    Uberall MA; Stehr K; Cherry JD; Heininger U; Schmitt-Grohé S; Laussucq S; Eckhardt T
    Dev Biol Stand; 1997; 89():83-9. PubMed ID: 9272335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure. Pertussis Vaccine Study Group.
    Heininger U; Cherry JD; Stehr K; Schmitt-Grohé S; Uberall M; Laussucq S; Eckhardt T; Meyer M; Gornbein J
    Pediatrics; 1998 Sep; 102(3 Pt 1):546-53. PubMed ID: 9738175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infant immunization with acellular pertussis vaccines in the United States: assessment of the first two years' data from the Vaccine Adverse Event Reporting System (VAERS).
    Braun MM; Mootrey GT; Salive ME; Chen RT; Ellenberg SS
    Pediatrics; 2000 Oct; 106(4):E51. PubMed ID: 11015546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection.
    Heininger U; Stehr K; Christenson P; Cherry JD
    Clin Infect Dis; 1999 Mar; 28(3):602-4. PubMed ID: 10194085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative efficacy trial in Germany in which infants received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) vaccine or DT vaccine.
    Stehr K; Cherry JD
    Dev Biol Stand; 1997; 89():58-62. PubMed ID: 9333571
    [No Abstract]   [Full Text] [Related]  

  • 11. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.
    Greco D; Salmaso S; Mastrantonio P; Giuliano M; Tozzi AE; Anemona A; Ciofi degli Atti ML; Giammanco A; Panei P; Blackwelder WC; Klein DL; Wassilak SG
    N Engl J Med; 1996 Feb; 334(6):341-8. PubMed ID: 8538704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of acellular pertussis-tetanus-diphtheria vaccines and whole-cell pertussis-tetanus-diphtheria vaccines in infancy.
    Korkmaz HA; Aydin A; Unal B
    Paediatr Int Child Health; 2014 Aug; 34(3):198-202. PubMed ID: 24621240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of diphtheria, tetanus, acellular pertussis and inactivated poliovirus (DTaP-IPV) vaccine.
    Daley MF; Yih WK; Glanz JM; Hambidge SJ; Narwaney KJ; Yin R; Li L; Nelson JC; Nordin JD; Klein NP; Jacobsen SJ; Weintraub E
    Vaccine; 2014 May; 32(25):3019-24. PubMed ID: 24699471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inadvertent administration of DTP and DT after age six as recorded in the Vaccine Adverse Event Reporting System.
    Zimmerman RK; Pellitieri TR
    Fam Pract Res J; 1994 Dec; 14(4):353-8. PubMed ID: 7863807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids.
    Englund JA; Anderson EL; Reed GF; Decker MD; Edwards KM; Pichichero ME; Steinhoff MC; Rennels MB; Deforest A; Meade BD
    Pediatrics; 1995 Sep; 96(3 Pt 2):580-4. PubMed ID: 7659480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.
    Knuf M; Habermehl P; Faber J; Bock HL; Sänger R; Bogaerts H; Clemens R; Schuind A; du Prel JB; Schmitt HJ
    Vaccine; 2006 Jul; 24(27-28):5627-36. PubMed ID: 16740348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous administration of Haemophilus influenzae type b vaccine with acellular or whole-cell pertussis vaccine: effects on reactogenicity and immune responses to pertussis vaccines.
    Rennels MB; Reed GF; Decker MD; Edwards KM; Pichichero ME; Deloria MA; Englund JA; Anderson EL; Steinhoff MC; Deforest A
    Pediatrics; 1995 Sep; 96(3 Pt 2):576-9. PubMed ID: 7659479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine.
    Lugauer S; Heininger U; Cherry JD; Stehr K
    Eur J Pediatr; 2002 Mar; 161(3):142-6. PubMed ID: 11998910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the tolerability of an acellular pertussis-containing vaccine given as the fifth booster dose in differently primed children.
    Kemmeren JM; Timmer SS; van der Maas NA; de Melker HE
    Vaccine; 2011 Jun; 29(26):4373-7. PubMed ID: 21514347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-response to a two-component acellular pertussis vaccine in infants and comparison with whole-cell vaccine.
    Auerbach BS; Lake AM; Wilson ME; Willingham FF; Shematek J; Moulton L; Deforest A; Halsey NA
    Biologicals; 1998 Jun; 26(2):145-53. PubMed ID: 9811522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.